Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study

by Malagoli, Piergiorigio , Parodi, Aurora , Burlando, Martina , Gisondi, Paolo , Guarneri, Claudio , Dapavo, Paolo , Marasca, Claudio , Dini, Valentina , Fabbrocini, Gabriella , Carmisciano, Luca , Offidani, Annamaria , Trifirò, Caterina , Malvaso, Dalma , Campanati, Anna , Dattola, Annunziata , Malara, Giovanna , Chiricozzi, Andrea , Fargnoli, Maria Concetta , Piaserico, Stefano , Castelli, Riccardo , Bianchi, Luca , Caro, Raffaele Dante Caposiena , Venturini, Marina

in Adalimumab / adalimumab biosimilar / adalimumab originator / Age / Algorithms / Analysis / Biological products / Hidradenitis Suppurativa / Monoclonal antibodies / Patients / Physiological aspects / Regression analysis / Skin diseases / Smoking / Tetracycline / Tetracyclines / Tumor necrosis factor-TNF

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study

2022

Confirm

Do you wish to request the book?

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study

Malagoli, Piergiorigio,

Parodi, Aurora,

Burlando, Martina,

Gisondi, Paolo,

Guarneri, Claudio,

Dapavo, Paolo,

Marasca, Claudio,

Dini, Valentina,

Fabbrocini, Gabriella,

Carmisciano, Luca,

Offidani, Annamaria,

Trifirò, Caterina,

Malvaso, Dalma,

Campanati, Anna,

Dattola, Annunziata,

Malara, Giovanna,

Chiricozzi, Andrea,

Fargnoli, Maria Concetta,

Piaserico, Stefano,

Castelli, Riccardo,

Bianchi, Luca,

Caro, Raffaele Dante Caposiena,

Venturini, Marina

2022

Overview

This study aimed to compare adalimumab originator vs. biosimilar in HS patients, and to evaluate the effect of a switch to a biosimilar, or a switch back to the originator, in terms of treatment ineffectiveness. Patients with a diagnosis of HS were enrolled from 14 Italian sites. Treatment ineffectiveness was measured using Hurley score. The major analyses were 1) comparison between the two treatment groups (non-switcher analysis), and 2) the cross-over trend of Hurley score between treatment switchers (switcher analysis). Cox and Poisson regression models were used to compare the treatment ineffectiveness between groups. A total of 326 patients were divided into four groups: 171 (52.5%) taking originator; 61 (18.7%) patients taking biosimilar; 66 (20.2%) switchers; 28 (8.6%) switchers from originator to biosimilar and switched. A greater loss of efficacy was observed in the group allocated to the biosimilar than the originator group. The switcher analysis showed an effectiveness loss in the biosimilar compared to the originator. These results seem to indicate that a switch from one drug to the other may lead to a greater risk of inefficacy. A return to the previous treatment also does not ensure efficaciousness.

Share this book

Add to My Shelf

Publisher

MDPI AG,MDPI

Subject

Adalimumab

/ adalimumab biosimilar

/ adalimumab originator

/ Age

/ Algorithms

/ Analysis

/ Biological products